Primary pneumonectomy, pneumonectomy after induction therapy, and salvage pneumonectomy: a comparison of surgical and prognostic outcomes.
Pneumonectomy
induction treatment
long term survival
salvage surgery
surgical and prognostic outcomes
Journal
Journal of thoracic disease
ISSN: 2072-1439
Titre abrégé: J Thorac Dis
Pays: China
ID NLM: 101533916
Informations de publication
Date de publication:
May 2020
May 2020
Historique:
entrez:
10
7
2020
pubmed:
10
7
2020
medline:
10
7
2020
Statut:
ppublish
Résumé
Surgical outcomes of pneumonectomy for lung cancer differ based on various therapeutic strategies. One hundred and fifty-one patients who underwent pneumonectomy were divided into three groups based on patients' therapeutic conditions: a primary pneumonectomy group (no preoperative treatment, n=137), an induction group (planned surgery after induction chemotherapy or chemoradiotherapy, n=10), and a salvage group (surgery for residual or enlarged lesions after radical non-operative therapies, n=4). Multivariate analysis showed that completeness of resection (P=0.003), subcategorization of whether there was no invasion, infiltration only to the main bronchus or pleura, or invasion of other deeper structures (P=0.008), and the presence or absence of mediastinal lymph node metastasis (P=0.033) were significant prognostic factors. Severe postoperative complications occurred in 5.1% (7/137), 20% (2/10), and 0% (0/4) in the primary pneumonectomy, induction, and salvage groups, respectively. Among patients with pN0-1 disease, the 3-year overall survival rate was 58.7% in the primary pneumonectomy group, 100% and 40% in cases with high and low pathological effects in the induction group, respectively, and 50% in the salvage group. Among patients with pN2 disease, this rate was 41.4% in the primary pneumonectomy group, and no patients survived for postoperative 2 years in the other groups. For patients undergoing pneumonectomy, subcategorization based on the invasion status (none/bronchus/pleura or other deeper structures) is a crucial prognostic factor. To consider pneumonectomy in the induction or salvage setting, selecting patients with pN0-1 disease may be mandatory.
Sections du résumé
BACKGROUND
BACKGROUND
Surgical outcomes of pneumonectomy for lung cancer differ based on various therapeutic strategies.
METHODS
METHODS
One hundred and fifty-one patients who underwent pneumonectomy were divided into three groups based on patients' therapeutic conditions: a primary pneumonectomy group (no preoperative treatment, n=137), an induction group (planned surgery after induction chemotherapy or chemoradiotherapy, n=10), and a salvage group (surgery for residual or enlarged lesions after radical non-operative therapies, n=4).
RESULTS
RESULTS
Multivariate analysis showed that completeness of resection (P=0.003), subcategorization of whether there was no invasion, infiltration only to the main bronchus or pleura, or invasion of other deeper structures (P=0.008), and the presence or absence of mediastinal lymph node metastasis (P=0.033) were significant prognostic factors. Severe postoperative complications occurred in 5.1% (7/137), 20% (2/10), and 0% (0/4) in the primary pneumonectomy, induction, and salvage groups, respectively. Among patients with pN0-1 disease, the 3-year overall survival rate was 58.7% in the primary pneumonectomy group, 100% and 40% in cases with high and low pathological effects in the induction group, respectively, and 50% in the salvage group. Among patients with pN2 disease, this rate was 41.4% in the primary pneumonectomy group, and no patients survived for postoperative 2 years in the other groups.
CONCLUSIONS
CONCLUSIONS
For patients undergoing pneumonectomy, subcategorization based on the invasion status (none/bronchus/pleura or other deeper structures) is a crucial prognostic factor. To consider pneumonectomy in the induction or salvage setting, selecting patients with pN0-1 disease may be mandatory.
Identifiants
pubmed: 32642175
doi: 10.21037/jtd.2020.03.19
pii: jtd-12-05-2672
pmc: PMC7330390
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2672-2682Informations de copyright
2020 Journal of Thoracic Disease. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/jtd.2020.03.19). YS serves as an unpaid editorial board member of Journal of Thoracic Disease from Aug 2019 to Jul 2021. The other authors have no conflicts of interest to declare.
Références
Gen Thorac Cardiovasc Surg. 2016 Nov;64(11):665-697
pubmed: 27590348
Lancet. 2015 Sep 12;386(9998):1049-56
pubmed: 26275735
Ann Thorac Surg. 2012 Jun;93(6):1807-12
pubmed: 22632486
J Thorac Cardiovasc Surg. 2015 Dec;150(6):1484-92; discussion 1492-3
pubmed: 26259994
Ann Thorac Surg. 2008 Oct;86(4):1076-83; discussion 1083
pubmed: 18805135
J Thorac Oncol. 2015 Jul;10(7):990-1003
pubmed: 26134221
Lung Cancer. 2018 Apr;118:134-138
pubmed: 29571992
Ann Thorac Surg. 2016 Sep;102(3):884-894
pubmed: 27476819
Ann Thorac Surg. 2008 Nov;86(5):1632-8; discussion 1638-9
pubmed: 19049763
J Thorac Oncol. 2017 Jul;12(7):1109-1121
pubmed: 28461257
Lung Cancer. 2014 May;84(2):151-5
pubmed: 24602394
Chest. 2002 Jun;121(6):1890-7
pubmed: 12065354
Lancet. 2009 Aug 1;374(9687):379-86
pubmed: 19632716
Ann Thorac Surg. 2001 Oct;72(4):1149-54
pubmed: 11603428
Ann Thorac Surg. 2004 Oct;78(4):1200-5; discussion 1206
pubmed: 15464470
Ann Thorac Surg. 2006 Jul;82(1):227-31
pubmed: 16798219
Interact Cardiovasc Thorac Surg. 2015 Nov;21(5):682-4
pubmed: 26323288
J Thorac Cardiovasc Surg. 2010 Jun;139(6):1424-30
pubmed: 20416887
J Thorac Oncol. 2013 Jul;8(7):915-22
pubmed: 23608815
Eur J Cardiothorac Surg. 2001 Sep;20(3):476-80
pubmed: 11509266
J Thorac Oncol. 2016 Jan;11(1):39-51
pubmed: 26762738